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Abstract
Background: Mechanisms linking chronic kidney disease (CKD) and adverse outcomes in acute coronary syndromes (ACS)
are not fully understood. Among potential key players, reduced nitric oxide (NO) synthesis due to its endogenous inhibitors,
asymmetric (ADMA) and symmetric (SDMA) dimethylarginine could be involved. We measured plasma concentration of
arginine, ADMA and SDMA and investigated their relationship with CKD and long-term outcome in non-ST-elevation
myocardial infarction (NSTEMI).
Methodology/Principal Findings: We prospectively measured arginine, ADMA, and SDMA at hospital admission in 104
NSTEMI patients. CKD was defined as an estimated glomerular filtration rate (eGFR) ,60 ml/min/1.73 m2. We considered a
primary end point of combined cardiac death and re-infarction at a median follow-up of 21 months. In CKD (n = 33) and no-
CKD (n = 71) patients, arginine and ADMA were similar, whereas SDMA was significantly higher in CKD patients (0.6560.23
vs. 0.4260.12 mmol/L; P,0.0001). Twenty-four (23%) patients had an adverse cardiac event during follow-up: 12 (36%) were
CKD and 12 (17%) no-CKD patients (P = 0.02). When study population was stratified according to arginine, ADMA and SDMA
median values, only SDMA (median 0.46 mmol/L) was associated with the primary end-point (P = 0.0016). In models adjusted
for age, hemoglobin and left ventricular ejection fraction, the hazard ratio (HR) for CKD and SDMA were high (HR 2.93,
interquartile range [IQR] 1.15–7.53; P = 0.02 and HR 6.80, IQR 2.09–22.2; P = 0.001, respectively) but, after mutual adjustment,
only SDMA remained significantly associated with the primary end point (HR 5.73, IQR 1.55–21.2; P = 0.009).
Conclusions/Significance: In NSTEMI patients, elevated SDMA plasma levels are associated with CKD and worse long-term
prognosis.
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Introduction
Growing evidence suggests that chronic kidney disease (CKD) is
associated with increased cardiovascular risk. Indeed, patients with
CKD have both traditional and non-traditional (related to the
underlying uremic state) risk factors, and the combination of these
favors the development of cardiovascular disease, contributes to
progression of CKD, and, ultimately, perpetuates mortality risk
[1,2]. The pervasive adverse influence of CKD has also been
demonstrated in the setting of acute coronary syndromes (ACS).
Among ACS patients, CKD doubles mortality rates and is third to
cardiogenic shock and congestive heart failure as a predictor of
mortality [3–7]. The mechanisms linking CKD and adverse
outcomes in patients with ACS, however, are not fully understood.
It is conceivable that the interplay among extensive co-morbidities,
underutilization of known cardio-protective therapies, more
frequent errors in dosing with excess toxicity from conventional
therapies may explain part of their excessive risk, but other
unidentified aspects related to the unique pathobiology of CKD
are possibly involved [1,7–9]. Recognition of the mechanisms
associated with increased risk of ACS patients with CKD is a
critical challenge to better determine where to concentrate the
efforts in future trials and to validate novel and effective therapies
for these high-risk patients.
Among other potential key players contributing to the increased
cardiovascular risk of CKD patients, dimethylarginines have
recently received attention. Reduced nitric oxide (NO) synthesis
due to increased levels of its circulating endogenous inhibitor,
asymmetric dimethylarginine (ADMA), has been suggested to
independently contribute to progression of CKD, to end-stage
renal disease, and death [10,11]. Plasma concentrations of ADMA
and of its isomer symmetric dimethylarginine (SDMA) are elevated
in patients with CKD and in other cardiovascular risk-states such
as hypertension, hypercholesterolemia, diabetes mellitus and
chronic heart failure, and are associated with oxidative stress
and endothelial dysfunction [12–18].
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The role of these inhibitors of NO, as well as their relative levels
in plasma, in ACS patients with CKD, are still unknown. Indeed,
in the systemic, as well as in the coronary circulation, NO relaxes
vascular smooth muscle to increase blood flow, and suppresses
processes involved in vascular disease, including leukocyte
adhesion and platelet aggregation [19,20]. All these effects might
be particularly relevant in ACS, a complex disease in which
coronary vasoconstriction and inflammatory and thrombotic
processes represent major pathogenetic factors.
In this study, we measured plasma concentration of metabolites
involved in the NO biosynthetic pathway, in particular arginine,
ADMA and SDMA, and we investigated their relationship with
renal function and long-term outcome of patients with ACS.
Materials and Methods
The Ethics Committee of the Centro Cardiologico Monzino
approved the study, and all patients gave written, informed
consent.
Study population
This prospective study was conducted at the Centro Cardiolo-
gico Monzino, University of Milan. All consecutive patients who
were admitted to the Coronary Care Unit (CCU) for non-ST-
elevation acute myocardial infarction (NSTEMI) between Sep-
tember 1, 2005 and October 24, 2007 were enrolled in the study.
We included patients who presented within 24 hours of the onset
of symptoms (characteristic chest pain with electrocardiographic
ST-segment depression or T wave inversion, and increase in
troponin I). We excluded patients receiving long-term peritoneal
or hemodialysis treatment. In order to prevent potential misclas-
sification of patients who might have developed acute kidney
injury, we also excluded patients with ACS-associated hemody-
namic (acute pulmonary edema, cardiogenic shock) or electrical
(life-threatening ventricular arrhythmias, high-degree conduction
disturbances) instability or other major clinical complications at
hospital presentation. Patients with angina precipitated by anemia
or other correctable factors, severe valvular heart disease,
malignancies, and severe liver disease, were also excluded.
Study protocol
At hospital admission, before any pharmacologic therapy was
started, venous blood samples were obtained for determination of
arginine, ADMA and SDMA plasma concentrations. We also
measured serum creatinine concentration in all patients at hospital
admission. Glomerular filtration rate (eGFR) was estimated using
the abbreviated Modification of Diet in Renal Disease (MDRD)
equation [21]. Chronic kidney disease was categorized as an
eGFR #60 ml/min per 1.73 m2 [22].
The choice of pharmacologic therapy and interventional
strategy for management of ACS was left to the discretion of the
CCU cardiologists. In all cases, early coronary angiography
(within 24 hours from hospital presentation) was performed, unless
contraindicated.
After hospital discharge, all patients were followed-up for at
least one year. During the follow-up, a combined end-point of
cardiac death and re-infarction (primary end point of the study)
was considered.
Clinical results were analyzed according to the presence (CKD
group) or absence (no-CKD group) of CKD.
For comparison, we considered a historical sample of 20 healthy
subjects (mean age 60, range 56–69 years) and of 10 CKD patients
(Stage 3 in all cases) without ACS (mean age 65, range 47–73
years; eGFR 5167 ml/min per 1.73 m2) evaluated in our
laboratory.
Blood sampling and biochemical measurements
Blood was collected from the antecubital vein into EDTA
containing tubes and plasma samples were obtained after
centrifugation (3000 g, 10 min. at 4uC). Aliquots of plasma were
stored at 280uC until analysis. Arginine, ADMA and SDMA
plasma concentrations were measured by liquid chromatography
method, performed using an HPLC system (ESA Bioscences,
Chelmford, MA, USA) equipped with fluorimetric detector FP-
1520 (Jasco, Tokyo, Japan) [23]. Briefly, organic solid phase
extraction onto Oasis MCX SPE cartridge (Waters Milford, MA,
USA) and basic derivatization with ortho-Phthaldialdehyde were
previously performed after adding MMA (0.2 mM) as internal
standard. Fifty mL of the purified sample were loaded onto Onyx
Monolythic C18 HPLC column (10064.6 mm, Phenomenex,
Torrance, CA, USA) eluted at 2 mL/min by 7% acetonitrile in
phosphate buffer 25 mM pH 6.5. Fluorescence was measured at
excitation and emission wavelengths of 340 and 455 nm,
respectively.
Data were obtained after comparison with calibration curves
using arginine, ADMA and SDMA pure standard solutions. The
intra- and inter-CVs % obtained with standard samples were
,5% for all the analytics considered. The limit of detection of
arginine was 0.041 mmol/L; it was 0.025 mmol/L for both
methylarginines.
Statistical analysis
Continuous variables are presented as mean6SD, and were
compared using the t-test for independent samples. Variables not
normally distributed are presented as median and interquartile
ranges (IQR), and compared with the Wilcoxon rank-sum test.
Categorical data were compared using the chi-square test or the
Fisher exact test, as appropriate.
Pearson correlation analysis was used to examine the linear
association between plasma arginine, ADMA, SDMA and eGFR.
Kaplan-Meier analysis was employed to generate time-to-event
curves for the clinical end point (cardiac death and myocardial
infarction), stratified according to values below or above medians
of arginine, ADMA or SDMA. Multivariable-adjusted hazard
ratios (HR) were computed by Cox proportional-hazard regression
analysis.
All tests were two-tailed, and a P value of less than 0.05 was
required for statistical significance. All calculations were computed
with the aid of the SAS software package (Version 9.2 SAS
Institute Inc, Cary, NC).
Results
A total of 104 consecutive patients with NSTEMI were included
in this study. Of these, 33 (32%) had CKD (Stage 3 in 29 patients
and Stage 4 in 4 patients) and 71 (68%) had normal renal function.
The baseline demographic and clinical characteristics of ACS
patients with and without CKD are shown in Table 1. Patients
with CKD were older and more likely to be treated with diuretics.
Moreover, they had significantly lower hemoglobin levels and
higher high-sensitivity C-reactive protein (hs-CRP) values.
In the whole population, plasma arginine was lower than our
reference values in healthy subjects (67.1616.7 mmol/L vs.
92.2617.5 mmol/L, respectively; P,0.0001), whereas ADMA
(0.43560.09 mmol/L vs. 0.46160.11 mmol/L, respectively;
P= 0.25) and SDMA (0.50160.19 mmol/L vs.
0.45760.11 mmol/L, respectively; P= 0.35) were similar. Arginine
Dimethylarginines and CKD in NSTEMI
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and ADMA levels were not significantly different in CKD and no-
CKD patients, whereas SDMA was significantly higher in CKD
patients (Table 1). Figure 1 shows arginine, ADMA and SDMA
values in healthy subjects, CKD controls, and in the two study
groups. Arginine values were lower in CKD and ACS patients and
ADMA levels were higher in CKD controls than in the other 3
groups. Finally, SDMA levels were higher in CKD patients than in
patients with normal renal function.
Throughout the entire study population, both ADMA and
SDMA were inversely correlated with eGFR, but this relationship
was stronger for SDMA (Figure 2). No relationship, instead, was
observed between arginine and eGFR (R=0.14; P= 0.16). In
addition, a significant correlation was observed between ADMA
and SDMA levels (R= 0.52; P,0.0001) and between SDMA and
hs-CRP values (R= 0.32; P= 0.018).
No patient died during hospital stay; 3 patients died during the
follow-up (median 21 months; IQR 7–33): 2 (6%) patients in CKD
Table 1. Baseline characteristics of the study patients.
CKD group no CKD group P value
(n=33) (n =71)
Clinical characteristics
Age (yrs) 7268 64611 ,0.001
Men, n (%) 22 (67%) 55 (77%) 0.24
Weight (kg) 74613 76613 0.46
Height (cm) 16768 16867 0.51
Smokers, n (%) 10 (30%) 24 (34%) 0.74
Diabetes mellitus, n (%) 11 (33%) 17 (24%) 0.31
Systemic hypertension, n (%) 19 (58%) 47 (66%) 0.39
Dyslipidemia, n (%) 19 (58%) 45 (63%) 0.57
Prior myocardial infarction, n (%) 8 (24%) 16 (23%) 0.84
Prior CABG, n (%) 5 (15%) 5 (7%) 0.28*
Prior PCI, n (%) 2 (6%) 7 (10%) 0.71*
Left ventricular ejection fraction, % 5668 55611 0.5
Medical therapy, n (%) 6 (18%) 8 (11%) 0.3
PCI, n (%) 22 (67%) 53 (75%) 0.39
CABG, n (%) 5 (15%) 10 (14%) 0.88
Medications at hospital presentation
ACE inhibitor or ARB, n (%) 17 (52%) 30 (42%) 0.37
Aspirin, n (%) 23 (70%) 47 (66%) 0.72
Diuretics, n (%) 8 (24%) 7 (10%) 0.05
Statins, n (%) 12 (36%) 24 (34%) 0.79
Beta-blockers, n (%) 9 (27%) 19 (27%) 0.95
Calcium channel blockers, n (%) 8 (24%) 16 (23%) 0.84
Oral hypoglycemics, n (%) 10 (30%) 12 (17%) 0.12
Laboratory measures
Serum creatinine (mg/dl) 1.37 (1.1–1.7) 0.98 (0.9–1.1) NA
eGFR (ml/min/1.73 m2) 4869 79612 NA
Hemoglobin (g/dl) 1361.5 1461.5 0.002
Total cholesterol (mg/dL) 188646 199638 0.2
LDL cholesterol (mg/dL) 109645 122635 0.11
HDL cholesterol (mg/dL) 46610 48611 0.37
Triglycerides (mg/dL) 120 (88–184) 113 (88–185) 0.971
hs-CRP (mg/L) 5.7 (4.4–8.7) 3.8 (2.2–5.8) 0.051
Arginine (mmol/L) 62617 68618 0.14
ADMA (mmol/L) 0.4660.1 0.4260.1 0.35
SDMA (mmol/L) 0.6560.2 0.4260.1 ,0.001
*By Fisher exact test.
1by Wilcoxon Rank Sum Test.
ACE = angiotensin-converting enzyme; ARB= angiotensin II receptor blocker; CABG= coronary artery bypass graft surgery; CKD= chronic kidney disease; CRP= C-
reactive protein; eGFR = estimated glomerular filtration rate; NA =not applicable; PCI = percutaneous coronary intervention.
doi:10.1371/journal.pone.0048499.t001
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group and 1 (1%) patient in no-CKD group. Overall, 24 (23%)
patients reached the combined primary end-point of death and re-
infarction during the follow-up: 12 (36%) patients in CKD group
and 12 (17%) patients in no-CKD group (P= 0.02 in Kaplan-
Meier analysis). Two (6%) and 14 (20%; P= 0.05) patients,
respectively, underwent an elective percutaneous coronary proce-
dure during the follow-up.
Figure 3 shows the Kaplan-Meier curves according to median
arginine (68.1 mmol/L), ADMA (0.42 mmol/L), and SDMA
(0.46 mmol/L) values stratification in the study population.
Notably, a significantly different incidence in the combined end
point of death and re-infarction was observed only for patients
stratified by median SDMA levels. Similar results were obtained
when the Kaplan-Meier curves were analyzed comparing the
upper tertile of arginine (.74.8 mmol/L; P= 0.33), ADMA
(.0.47 mmol/L; P= 0.10) and SDMA (.0.5 mmol/L; P= 0.003)
with the lower two tertiles.
Table 2 reports the HRs for the primary end point obtained by
different Cox models. In models adjusted only for age, hemoglobin
and left ventricular ejection fraction, HR for CKD and SDMA
were high but, after mutual adjustment, only SDMA remained
significantly associated with the primary end point.
Discussion
The most significant finding of the present study is that plasma
levels of SDMA, measured at hospital presentation, are elevated in
NSTEMI patients with CKD, and are independent early
predictors of the composite outcome of cardiac death and
myocardial infarction.
Chronic kidney disease is present in a substantial proportion of
patients with ACS and represents a potent and independent risk
factor for short- and long-term adverse outcome [4–7,9]. The
reasons for this close association, however, are not completely
clear and cannot be entirely explained by the clustering of the
traditional cardiovascular risk factors. Besides clinical and
therapeutic differences, it is likely that peculiar characteristics of
renal insufficiency may play a considerable role [1,24]. It has been
hypothesized that the excessive risk associated with CKD can be
attributed, at least in part, to endothelial dysfunction and reduced
Figure 1. Arginine, ADMA and SDMA plasma levels. Arginine
(panel A), asymmetric dimethylarginine (ADMA; panel B), and symmetric
dimethylarginine (SDMA; panel C) plasma levels (mean6SD values) in
healthy subjects (n = 20), in controls with chronic kidney disease (CKD;
n = 10), and in NSTEMI patients without (n = 71) and with (n = 33) CKD.
doi:10.1371/journal.pone.0048499.g001
Figure 2. Relationships between NO synthesis inhibitors and
renal function. Relationship between asymmetric (ADMA; upper
panel) and symmetric (SDMA; lower panel) dimethylarginine plasma
levels and estimated glomerular filtration rate (eGFR) in the study
population.
doi:10.1371/journal.pone.0048499.g002
Dimethylarginines and CKD in NSTEMI
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Figure 3. Kaplan-Meier survival analyses during follow-up. Composite outcomes of cardiac death and myocardial infarction according to
concentrations of plasma arginine (panel A), asymmetric dimethylarginine (ADMA; panel B), and symmetric dimethylarginine (SDMA; panel C), divided
by median levels. P values by log-rank test are shown.
doi:10.1371/journal.pone.0048499.g003
Dimethylarginines and CKD in NSTEMI
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bioavailability of NO, a potential link between CKD and
cardiovascular disease.
Elevated plasma concentrations of ADMA have been found in
various clinical settings, ranging from critically ill patients admitted
to the Intensive Care Unit [25] to patients with CKD [26] and
end-stage renal disease [10], with stable coronary artery disease
[27], and to those undergoing coronary angiography [28] and
non-cardiac surgery [29]. In all these conditions, elevation of
ADMA has been identified as an independent risk factor for future
adverse cardiovascular events and death. It has been proposed
that, by inhibiting NO synthesis, ADMA may contribute directly
to endothelial dysfunction, depression of cardiac function,
progression of chronic renal disease, and organ failure
[12,30,31]. Recently, ADMA has also been measured in patients
with ACS [32–34]. In a study by Cavusoglu et al. [33], plasma
levels of ADMA were measured in a cohort of 182 men with ACS.
The authors found that elevated plasma levels of ADMA were
powerful and independent predictors of adverse cardiovascular
outcomes. In particular, ACS patients who had the upper tertile of
baseline ADMA had a significantly higher two-year mortality than
those in the lower two tertiles combined (23.8% vs. 8.6%;
P=0.004).
In most previous studies, investigators focused mainly on
ADMA and, until recently, little attention has been paid to the
role of its structural isomer SDMA. To our knowledge, this is the
first study evaluating the association between plasma levels of both
dimethylarginines and long-term outcome in ACS. In our study,
no increase in ADMA levels in plasma were found in comparison
with healthy subjects, not even when the whole study group, as
well as the two subsets of patients stratified according to the
presence or absence of CKD, were considered. Moreover, no
significant association between ADMA levels and clinical outcome
was observed. Some important clinical (patients characteristics,
type [STEMI vs. NSTEMI] and severity of ACS), methodological
and analytical (ELISA vs. HPLC) differences among studies may
explain the apparent inconsistency between our data and those
previously published, regarding the capacity of ADMA to predict
cardiac events in ACS [32–35].
Both dymethylarginines are physiologically present in plasma as
a product of normal protein turnover. However, as SDMA is
mainly eliminated by renal excretion, whereas ADMA is largely
metabolized, it is not surprising to find a closer relationship
between renal impairment and SDMA than with ADMA. The
increase in SDMA observed in our study in CKD patients, as well
as the good correlation found between SDMA and eGFR, are in
agreement with a previous meta-analysis showing a strong
correlation between SDMA and renal function [36]. As there is
a high concentration of the ADMA degrading enzyme (DDAH) in
the kidney, it is also conceivable that the decline in renal excretory
function is paralleled by a reduction of DDAH activity (in the
kidney). This, and the fact that about 10% of ADMA formed is
also excreted by the kidneys, might explain why also ADMA is
weakly related to parameters of renal function in some of the
studies, including the present one.
When patients were stratified by median SDMA plasma
concentration, a significant difference in long-term clinical
outcome was found. Notably, SDMA was a stronger predictor of
cardiac events, in particular re-infarction, than CKD, as defined
according to GFR estimated by serum creatinine. The mecha-
nism(s) linking SDMA and outcome, however, remains uncertain.
Several mechanisms may potentially explain this association. First,
SDMA might directly influence the outcome of ACS patients by
participating to cause reduction in NO production and induction
of endothelial dysfunction. Although SDMA has not been shown
to directly affect NO synthase activity in vitro [37], we cannot
exclude its influence on the production of NO in some clinical
conditions characterized by its increase in plasma. Indeed, SDMA
may have an indirect effect on NO synthesis, by inhibiting the y+
transporter that mediates the intracellular uptake of L-arginine
and renal tubular arginine absorption [38,39]. These two
mechanisms might indirectly inhibit NO synthesis by interfering
with L-arginine uptake. Second, SDMA accumulation in the
plasma due to reduced renal clearance might only reflect kidney
dysfunction. Many studies have shown a good correlation between
SDMA and established estimates of GFR in humans, as well as in
animal models [40]. Based on these premises, SDMA fulfills all
criteria for an ideal GFR marker, i.e. stable production rate, free
glomerular filtration, and lack of tubular reabsorption [36]. On the
other hand, estimates of GFR from serum creatinine may lack in
necessary sensitivity due to considerable inter-individual variability
in muscle mass, protein intake, age, and sex [41]. This limitation is
even more critical in ACS, a clinical setting in which no renal
baseline conditions are available and serum creatinine levels at
hospital admission cannot be considered a true stable value
because the occurrence of a transient hemodynamic impairment,
which in turn results in the increase of serum creatinine in the
plasma. Moreover, creatinine increase may lag far behind
glomerular filtration changes, because of its delayed rise after
renal injury, due to the slow variations in its metabolism and the
exponential relationship existing between these two variables.
Thus, it is likely that SDMA is able to more accurately reflect
glomerular filtration than creatinine and its levels in plasma may
better identify the ‘‘true’’ CKD patients with a worse prognosis.
According to this hypothesis, the lower SDMA values in CKD
controls than in NSTEMI patients with CKD, might be explained
by the higher eGFR in the former than in the latter group (5167
and 4869 ml/min per 1.73 m2, respectively). The list of
mechanisms through which SDMA might directly contribute to
unfavorable outcomes in ACS patients, however, is most likely not
yet complete. In our study, SDMA levels in plasma were
correlated with hs-CRP levels at hospital presentation, suggesting
a possible role in promoting inflammatory response. A recent
Table 2. Cox regression analysis for the primary end point of
the study (composite outcome of cardiac death and
myocardial infarction).
Model Variable Adjusted HR 95% CI P value
1 CKD 2.93 1.15–7.53 0.02
2 Arginine 0.95 0.37–2.42 0.91
3 ADMA 2.24 0.89–5.65 0.08
4 SDMA 6.80 2.09–22.2 0.001
5 Arginine 1.18 0.45–3.09 0.72
CKD 3.04 1.16–7.97 0.02
6 ADMA 1.84 0.71–4.79 0.21
CKD 2.52 0.96–6.64 0.06
7 SDMA 5.73 1.55–21.2 0.009
CKD 1.35 0.49–3.71 0.55
Hazard ratios (HR) in models 1–4 are adjusted for age, hemoglobin and left
ventricular ejection fraction; HRs in models 5–7 are also mutually adjusted.
HRs for CKD are vs. no-CKD; for all other variables, HRs are for values above vs.
below median.
ADMA=asymmetric dimethylarginine; CKD= chronic kidney disease;
CI = confidence intervals; SDMA= symmetric dimethylarginine.
doi:10.1371/journal.pone.0048499.t002
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study has shown that SDMA is involved in the inflammatory
process of CKD, by activating intracellular monocytic expression
of interleukin 6 and tumor necrosis factor-alpha in vitro, whereas
ADMA does not. This pro-inflammatory profile has been
confirmed in a clinical study in which SDMA was associated with
inflammatory markers [42]. Finally, a possible procoagulant state
due to induction of tissue factor expression by peripheral
monocytes, like that demonstrated for ADMA in ACS patients,
cannot be excluded for SDMA [34].
Our data provide a basis for future studies which will investigate
whether determination of SDMA, as well as its pharmacologic
modulation, may help to guide care and improve outcomes of
ACS patients. Irrespectively of its potential role in the pathophys-
iology of long-term adverse cardiac events, SDMA determination
may have a considerable clinical usefulness in risk stratification of
ACS patients. In particular, measurement of SDMA might allow
for a more accurate and early recognition of CKD patients, who
may require drug dose adjustments, renal prophylactic strategies,
and targeted therapeutic interventions. Moreover, in these
patients, long-term prognostic stratification may be more precise.
Notably, in our study, we identified a potential cutoff value of
SDMA of 0.46 mmol/L (median value) for risk classification.
Our study has some limitations. First, the size of the population
is small and the findings need to be confirmed in larger studies.
Similarly, the number of cardiac events is small, possibly due to the
exclusion of high-risk patients from the study. Although this may
represent an important limitation, the impossibility to differentiate
between CKD and acute kidney injury on the bases of a single
creatinine value measured at hospital admission, could have
almost certainly lead to overestimate the number of patients with
CKD. Nonetheless, the ADMA and SDMA levels in ACS patients
developing acute kidney injury, as well as their possible association
with short- and long-term outcomes, are not known and should be
matter of future investigation. Second, being an observational
study, our data do not unequivocally demonstrate that SDMA
increase in plasma levels contributes to mortality and re-infarction.
Further studies should investigate the relationship between SDMA
increase and endothelial dysfunction, possibly evaluating endo-
thelial-dependent vasodilatory response. Finally, we cannot
exclude the possibility that some medications, taken by patients
before hospital admission, may have influenced our results.
Indeed, ADMA concentration has been shown to significantly
decrease in ACS patients after a short-term medical therapy [32].
Conclusions
In NSTEMI patients, CKD is associated with increased SDMA
plasma levels and worse long-term prognosis. Further studies are
needed to establish whether the increased mortality risk of CKD
patients is due to SDMA-induced impaired NO synthesis and
whether pharmacologic modulation of SDMA may improve their
outcomes.
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